Dividend Policy - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares to all shareholders based on a total share capital of 204,000,000 shares as of December 31, 2014[5]. - The company implemented a cash dividend policy, distributing RMB 0.20 per share for the 2013 fiscal year, totaling RMB 4,080,000, and for the 2014 fiscal year, it plans to distribute RMB 1.00 per share, totaling RMB 20,400,000[89][92]. - The company's net profit for 2014 was RMB 49,021,329.28, with a total distributable profit of RMB 174,486,624.04 after accounting for the legal reserve and previous dividends[92]. - The cash dividend for 2014 represents 100% of the profit distribution total, reflecting the company's commitment to returning value to shareholders[92]. - The company has a clear cash dividend policy that aligns with its articles of association and shareholder resolutions[90]. Financial Performance - The company achieved operating revenue of 375,601,838.81 CNY, an increase of 19.76% compared to the previous year[29]. - Net profit attributable to shareholders reached 40,567,979.11 CNY, reflecting a significant growth of 640.27% year-over-year[29]. - The net cash flow from operating activities was 73,312,902.53 CNY, up 135.56% from the previous year[29]. - The total assets at the end of 2014 were 848,527,462.37 CNY, representing a 5.82% increase from the previous year[29]. - The company reported a total profit of 48,388,079.29 CNY, which is a 734.35% increase year-over-year[29]. - The weighted average return on equity was 5.57%, an increase of 4.79 percentage points compared to the previous year[29]. - The company achieved a total revenue of ¥375,601,838.81 in 2014, representing a year-on-year growth of 19.76%[33]. - The main business revenue was ¥375,106,916.25, with a year-on-year increase of 19.81%[33]. - The sales volume reached 159,985,212.9 boxes, up 16.69% compared to 137,098,441 boxes in 2013[33]. - The company’s gross profit margin for raw materials was 78.47%, slightly increasing from 77.94% in the previous year[36]. Risks and Challenges - The company reported potential risks including rising production costs, R&D and drug registration challenges, policy changes, product quality fluctuations, safety and environmental concerns, and talent shortages[12]. - The company acknowledges potential risks related to drug registration, policy changes, product quality, and talent shortages as it expands[85]. - The company faces risks related to rising production costs due to increasing prices of raw materials and labor[84]. Operational Stability - The company has maintained its main business without changes since its listing, indicating stability in its operational focus[18]. - The company is committed to ensuring the accuracy and completeness of its financial reports, with key personnel affirming the integrity of the annual report[4]. - The company operates under the supervision of the China Securities Regulatory Commission and is listed on the Shenzhen Stock Exchange[15]. - The company has a registered capital structure that has remained unchanged since its initial registration in 2001[18]. Research and Development - The company added 3 new production licenses and obtained 9 invention patents during the reporting period[30]. - R&D expenditure was ¥15,910,887.23, accounting for 4.24% of total revenue, down from 5.58% in 2013[40]. - The company received 9 patents and had 3 patent applications accepted during the reporting period[41]. - The company will increase R&D investment and improve innovation incentive mechanisms to enhance technological innovation levels[84]. Marketing and Sales - The company is actively enhancing its marketing system and expanding its sales team to improve overall sales performance[30]. - The company has formed a marketing network covering commercial channels, retail pharmacies, and hospital clinics, facilitating product promotion and market demand responsiveness[54]. - The top five customers contributed ¥87,102,039.06, accounting for 23.19% of total annual sales[34]. - The total procurement amount from the top five suppliers was ¥66,389,893.31, representing 36.14% of total procurement[38]. Governance and Compliance - The company has maintained a robust governance structure and investor interaction platform to protect shareholder rights and ensure transparency[93]. - The company has established a comprehensive quality management system to ensure zero defects in product quality, relying on high-quality raw materials and strict control throughout the production process[95]. - The company has established a comprehensive internal information management system to prevent insider trading and ensure compliance with disclosure regulations[168]. - The governance structure complies with the requirements set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[167]. Investments and Projects - The company has committed to several investment projects, with a total commitment of RMB 23.60 million[67]. - The company has not changed the purpose of any raised funds during the reporting period[64]. - The company has not engaged in entrusted financial management, derivative investments, or entrusted loans during the reporting period[60][61][62]. - The company has established a complete pharmaceutical business industry chain, enhancing its ability to mitigate operational risks[54]. Subsidiaries and Mergers - The company established a wholly-owned subsidiary, Shaoxing Yatai Pharmaceutical Co., Ltd., with an investment of RMB 40 million, which was registered on April 28, 2014, and included in the consolidated financial statements from its establishment date[88]. - Zhejiang Taist Biotech Co., Ltd. achieved revenue of CNY 8,413,032.73, with a net profit of CNY 908,198.09 during the reporting period[77]. - The company completed the absorption merger of its wholly-owned subsidiary Shaoxing Kairijie Biotechnology Co., Ltd. by Zhejiang Taisite Biotechnology Co., Ltd., with the registered capital of Taisite increasing from RMB 5 million to RMB 15 million[130]. - The merger aims to optimize management structure and improve operational efficiency, with no substantial impact on the company's financial status[105]. Employee and Management Structure - As of December 31, 2014, the company had a total of 799 employees, with 755 in the parent company and 44 in subsidiaries[162]. - The employee composition included 417 production personnel, 156 sales personnel, 141 technical personnel, 15 financial personnel, and 70 management personnel[162]. - The company has established a performance evaluation system that links the compensation of senior management to the company's operational goals and individual performance[156]. - The total compensation for the chairman, Chen Yaogen, is 2.8 million CNY, while the total compensation for the vice chairman and general manager, Lü Xuxing, is 3.0 million CNY[158]. Audit and Financial Reporting - The audit committee reviewed the 2014 annual financial report and confirmed it accurately reflects the company's financial status as of December 31, 2014, and its operating results for the year[176]. - The audit opinion states that the financial statements fairly reflect the company's financial position as of December 31, 2014, and its operational results for the year[198]. - The audit was conducted by Tianjian Accounting Firm, with a standard unqualified audit opinion issued on March 19, 2015[193]. - The company has not experienced any major accounting errors requiring restatement during the reporting period[87].

Financial Performance - Operating revenue for the reporting period was ¥81,934,395.66, representing a year-on-year increase of 27.58%[6] - Net profit attributable to shareholders of the listed company was ¥5,448,526.18, up 46.82% year-on-year[6] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,684,496.42, an increase of 111.77% compared to the same period last year[6] - Basic earnings per share for the reporting period were ¥0.03, reflecting a 50.00% increase year-on-year[6] - The weighted average return on net assets was 0.74%, up from 0.21% in the previous year[6] - The net profit attributable to shareholders for 2014 is expected to range from 38 million to 43 million CNY, representing a year-on-year increase of 593.41% to 684.64%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥791,357,878.69, a decrease of 1.31% compared to the end of the previous year[6] - Net assets attributable to shareholders of the listed company increased by 3.54% to ¥734,933,257.52[6] - The total number of ordinary shareholders at the end of the reporting period was 10,194[10] - Short-term borrowings decreased by 100.00% compared to the beginning of the period, as the company repaid bank loans during the reporting period[14] Cash Flow - The company reported a net cash flow from operating activities of ¥40,421,601.21, an increase of 110.96% year-on-year[6] - Net cash flow from operating activities increased by 110.96% year-on-year, driven by higher cash receipts from sales of goods and services[14] - The net cash flow from investing activities decreased by 232.88% year-on-year, mainly due to increased cash payments for fixed and intangible asset acquisitions[14] Receivables and Prepayments - Prepayments increased by 412.28% compared to the beginning of the period, mainly due to increased advance payments for raw materials[14] - Other receivables increased by 789.93% compared to the beginning of the period, primarily due to land guarantee deposits paid for a newly established wholly-owned subsidiary[14] Tax and Expenses - The company's income tax expense increased by 1016.29% year-on-year, mainly due to profit growth during the reporting period[14] - The deferred income tax assets decreased by 75.59% compared to the beginning of the period, primarily due to the reduction in deferred tax assets from profit offsetting previous losses[14] Investments - Zhejiang Yatai Pharmaceutical Co., Ltd. reported a total investment of 1,190,160.00 yuan in Zhejiang Zhenyuan Co., Ltd. with a holding of 229,110 shares, representing 0.14% of the total shares[19] - The book value of the investment in Zhejiang Zhenyuan Co., Ltd. is 4,893,789.60 yuan, with no reported gains during the reporting period[19] Future Outlook - The company anticipates a gradual improvement in performance due to the optimization of sales systems and market channels, as well as growth in revenue from quality products[18] Construction and Projects - The construction in progress increased by 71.16% compared to the beginning of the period, mainly due to increased project and equipment costs for a new production line[14]

Financial Performance - The company's operating revenue for the first half of 2014 was ¥194,886,991.85, representing a 30.04% increase compared to ¥149,871,845.76 in the same period last year[19]. - The net profit attributable to shareholders was ¥22,531,617.95, a significant increase of 389.60% from a loss of ¥7,780,168.60 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥19,939,970.32, up 303.94% from a loss of ¥9,777,290.42 in the same period last year[19]. - The net cash flow from operating activities was ¥8,535,043.35, a 322.26% increase compared to a negative cash flow of ¥3,840,073.15 in the previous year[19]. - Basic earnings per share rose to ¥0.11, compared to a loss of ¥0.04 per share in the same period last year, marking a 375.00% improvement[19]. - Operating profit reached ¥23,943,010.77, reflecting a significant growth of 312.06% compared to the previous year[28]. - The total profit for the current period is CNY 26,797,109.98, compared to a loss of CNY 9,052,617.11 in the previous period[118]. - The total comprehensive income for the current period is CNY 22,759,467.84, compared to a loss of CNY 7,721,745.55 in the previous period[118]. Assets and Liabilities - Total assets at the end of the reporting period were ¥786,449,539.37, a decrease of 1.92% from ¥801,862,083.87 at the end of the previous year[19]. - The total liabilities decreased to ¥57,240,101.56 from ¥91,143,328.41, showing improved financial health[116]. - The company's retained earnings increased to ¥154,105,584.01 from ¥134,447,427.69, indicating a positive trend in profit retention[116]. - The total owner's equity at the end of the reporting period was CNY 734,312,960, up from CNY 707,220,630 at the end of the previous year[138]. Investments and Capital Expenditures - Total investment during the reporting period was ¥40,000,000, a 100% increase compared to the previous year[37]. - The company has committed to various investment projects with a total investment amount of RMB 235.96 million[47]. - The new production line for freeze-dried powder injections has an investment progress of 85.72%[48]. - Cash outflow for capital expenditures was ¥58,775,009.72, significantly higher than ¥17,228,307.80 in the previous period, indicating aggressive investment in assets[128]. Research and Development - Research and development investment decreased by 18.96% to ¥7,210,494.72[30]. - The company obtained 5 invention patents and filed for 7 new products during the reporting period[31]. Corporate Governance and Compliance - The company maintained compliance with corporate governance standards as per relevant regulations and guidelines[68]. - The company did not engage in any asset acquisitions, sales, or mergers during the reporting period[72][75]. - There were no significant litigation or arbitration matters during the reporting period[69]. - The company has not faced any penalties or corrective actions during the reporting period[91]. Shareholder Information - The company distributed a cash dividend of RMB 0.20 per share, totaling RMB 4.08 million, based on a total share capital of 204 million shares as of December 31, 2013[63]. - The total number of common shareholders at the end of the reporting period was 10,025[97]. - The total number of shares issued was 204,000,000, with 43.89% being restricted shares and 56.11% being unrestricted shares[97]. Cash Flow - The net cash flow from operating activities increased to ¥12,203,225.09, compared to a negative cash flow of ¥3,130,403.17 in the previous period, marking a significant turnaround[128]. - Cash inflow from investing activities rose to ¥5,622,250.00 from ¥351,020.00, showing a substantial increase in investment returns[128]. - The ending cash and cash equivalents balance decreased to ¥190,500,437.95 from ¥216,092,053.38, a decline of approximately 11.8%[129]. Future Outlook - The company expects a net profit of between RMB 24 million and RMB 28 million for the first nine months of 2014, a turnaround from a net loss of RMB 4.069 million in the same period last year[61]. - The company plans to continue focusing on expanding its long-term investments and improving operational efficiency in the upcoming periods[117]. Financial Reporting - The financial report for the half-year period was not audited[108]. - The company's financial reports reflect its financial position, operating results, and cash flows accurately and completely[142]. - The company’s financial statements are consolidated, including all subsidiaries under its control[148].

证券代码：002370 证券简称：亚太药业 公告编号：2014-022 浙江亚太药业股份有限公司 2014 年第一季度报告正文 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 2014 年 04 月 1 浙江亚太药业股份有限公司 2014 年第一季度报告正文 公司负责人陈尧根、主管会计工作负责人何珍及会计机构负责人(会计主管 人员)何珍声明：保证季度报告中财务报表的真实、准确、完整。 浙江亚太药业股份有限公司 第一节 重要提示 2014 年第一季度报告正文 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | 876,832.12 | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 一标准定额或定量享受的政府补助除外） | 1,512,000.00 | | | 除上述各项之外的其他营业外收入和支出 | 330.00 | | | 减：所得 ...

Financial Performance - The company achieved operating revenue of ¥313,637,218.04, a decrease of 0.76% compared to the previous year[34]. - The net profit attributable to shareholders was ¥5,480,181.49, representing a significant increase of 121.31% year-over-year[34]. - The net cash flow from operating activities reached ¥31,122,817.17, marking a substantial increase of 396.21% compared to the previous year[34]. - The total assets at the end of the year were ¥801,862,083.87, a decrease of 1.98% from the previous year[34]. - The weighted average return on equity improved to 0.78%, up from -3.56% in the previous year[34]. - The company reported a total revenue of 313,637,218.04 yuan in 2013, which is a slight decline of 0.76% from 316,044,644.25 yuan in 2012[52]. - The company’s R&D expenditure for 2013 was 17,502,618.92 yuan, accounting for 5.58% of total revenue, down from 5.91% in 2012[52]. - The company achieved a net asset value of 709,825,703.70 yuan, reflecting a 0.84% increase from the previous year[52]. - The company’s financial expenses improved by 22.16%, reducing from -4,828,223.52 yuan in 2012 to -3,758,270.18 yuan in 2013[52]. Dividends and Fundraising - The company proposed a cash dividend of RMB 0.20 per 10 shares (including tax) based on the total share capital as of December 31, 2013[5]. - The company reported a cash dividend of RMB 0.20 per share for 2013, totaling RMB 4,080,000, which is 74.45% of the net profit attributable to shareholders[108]. - Total fundraising amount reached RMB 447.71 million, with RMB 30.54 million cumulatively invested[81]. - In 2013, the actual use of fundraising was RMB 47.48 million, including RMB 21.79 million for project use and RMB 25.70 million for working capital[81]. - The balance of fundraising as of December 31, 2013, was RMB 163.42 million, including interest net of bank fees[81]. Market and Industry Risks - The company reported a significant risk of changes in national policies and drug pricing, which may impact future performance[12]. - The company’s future plans and development strategies are subject to market risks, and investors are advised to be cautious[5]. - The pharmaceutical manufacturing industry experienced a sales volume of 137,098,441 units, a decrease of 14.04% compared to 2012[39]. - The company faces risks from changes in national policies and drug pricing pressures due to ongoing healthcare reforms[105]. Corporate Governance - The company has maintained its corporate governance structure, which includes a board of directors and supervisory board[14]. - The company’s financial report was confirmed to be true, accurate, and complete by its management, ensuring reliability for investors[4]. - The company operates under the supervision of the China Securities Regulatory Commission and the Shenzhen Stock Exchange, ensuring compliance with regulations[9]. - The company has established and revised various governance systems, including the internal information management system and the insider information registration management system, to enhance compliance and governance[186]. - The company has actively improved its governance structure in accordance with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange[187]. Research and Development - The company increased its R&D efforts, resulting in the acquisition of 2 invention patents and 2 design patents during the reporting period[36]. - The company reported a total of 16 products under review or pending review by the National Medical Products Administration[36]. - The company is accelerating new drug development, focusing on the research and clinical application of the new drug racemic ketoprofen transdermal patch[103]. - The company plans to enhance R&D investment and operational efficiency to adapt to industry policy changes and challenges[102]. - The company will focus on developing chemical drug formulations, raw materials, and diagnostic reagents in 2014[102]. Operational Developments - The company established a marketing department for estradiol to enhance the market brand of its product[35]. - The company has made progress in the new GMP certification, with all dosage forms passing the certification[35]. - The company has established a complete pharmaceutical business chain, enhancing its ability to mitigate operational risks[66]. - The company is actively seeking industrial land in Shaoxing to expand its production facilities, which is currently facing uncertainty[86]. - The company is expanding its emerging businesses, particularly in raw materials and diagnostic reagents, to create new profit growth points[103]. Management and Leadership - The company has a total of 10 current directors and supervisors, with a mix of experience in various sectors including pharmaceuticals and real estate[167][168]. - The management team has a strong educational background, with several members holding advanced degrees and professional certifications[169]. - The company established a performance evaluation system linking senior management's remuneration to operational performance and individual contributions[175]. - The company is committed to maintaining transparency in its remuneration practices and aligning them with industry standards[175]. - The current management team has been in place since December 2013, indicating stability in leadership[166]. Shareholder Information - The total number of shares is 204,000,000, with 61.87% being restricted shares before the change, which decreased to 43.89% after the change[148]. - The largest shareholder, Zhejiang Apac Group Co., Ltd., holds 45% of the shares, amounting to 91,800,000 shares, with 68,850,000 shares under lock-up[154]. - The company experienced a decrease in the number of shareholders from 6,335 to 6,056 during the reporting period[154]. - The company’s major shareholder, Shaoxing Apac Real Estate Co., Ltd., holds 13.28% of the shares, totaling 27,081,000 shares, with 20,310,750 shares pledged[154]. - The company has not reported any losses from its securities investments during the reporting period[71]. Compliance and Legal Matters - There were no significant legal disputes or media controversies during the reporting period[118][119]. - The company has not faced any regulatory measures or administrative penalties related to insider trading during the reporting period[189]. - The company has not reported any unfulfilled commitments or reasons for non-compliance during the reporting period[141]. - The company has not engaged in any significant related party transactions during the reporting period[125]. - The company has not provided any external guarantees, including to subsidiaries[134].